Memory Enhancement Center, Eatontown, New Jersey, USA.
J Alzheimers Dis. 2010;22(2):401-4. doi: 10.3233/JAD-2010-101548.
The recent failure of semagacestat in two large Phase III studies questions the value of γ-secretase inhibitors in treating Alzheimer's disease. Understanding the reasons of this setback may be important for the future research on effective treatments for this devastating disease.
最近两项大型 III 期研究中司美加群的失败，使 γ-分泌酶抑制剂治疗阿尔茨海默病的价值受到质疑。了解这一挫折的原因，对于未来寻找这种破坏性疾病的有效治疗方法的研究可能非常重要。
